- Home
- EDF vs ACRS Comparison
EDF vs ACRS Comparison
Compare EDF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- ACRS
- Stock Information
- Founded
- EDF 2010
- ACRS 2012
- Country
- EDF United States
- ACRS United States
- Employees
- EDF N/A
- ACRS N/A
- Industry
- EDF Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- ACRS Health Care
- Exchange
- EDF Nasdaq
- ACRS Nasdaq
- Market Cap
- EDF 148.6M
- ACRS 132.0M
- IPO Year
- EDF N/A
- ACRS 2015
- Fundamental
- Price
- EDF $4.99
- ACRS $2.60
- Analyst Decision
- EDF
- ACRS Strong Buy
- Analyst Count
- EDF 0
- ACRS 5
- Target Price
- EDF N/A
- ACRS $11.00
- AVG Volume (30 Days)
- EDF 160.6K
- ACRS 956.3K
- Earning Date
- EDF 01-01-0001
- ACRS 02-25-2025
- Dividend Yield
- EDF 13.14%
- ACRS N/A
- EPS Growth
- EDF N/A
- ACRS N/A
- EPS
- EDF N/A
- ACRS N/A
- Revenue
- EDF N/A
- ACRS $27,079,000.00
- Revenue This Year
- EDF N/A
- ACRS N/A
- Revenue Next Year
- EDF N/A
- ACRS N/A
- P/E Ratio
- EDF N/A
- ACRS N/A
- Revenue Growth
- EDF N/A
- ACRS 26.35
- 52 Week Low
- EDF $3.51
- ACRS $0.95
- 52 Week High
- EDF $5.50
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- EDF 53.40
- ACRS 44.53
- Support Level
- EDF $4.96
- ACRS $2.31
- Resistance Level
- EDF $5.13
- ACRS $2.57
- Average True Range (ATR)
- EDF 0.08
- ACRS 0.18
- MACD
- EDF 0.02
- ACRS 0.01
- Stochastic Oscillator
- EDF 68.89
- ACRS 59.79
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund invests predominantly invests in fixed income securities and other instruments economically tied to emerging market countries.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.